Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matritech's NMP22

This article was originally published in The Gray Sheet

Executive Summary

Test kit for detecting previously undiagnosed bladder cancer is scheduled for FDA panel review on Dec. 13, the company reports Oct. 26. The kit is currently cleared in the U.S. for monitoring the recurrence of bladder cancer, and is approved for use in screening in Japan. U.S. approval is anticipated in early 2000. Clinical study results submitted to FDA show the test to be 85% sensitive in detecting later stage, more life-threatening forms of bladder cancer in previously undiagnosed patients who presented a risk profile of smoking and blood in urine. The test kit was also more than twice as sensitive as urine cytology in identifying early-stage, low-grade bladder cancer. When used in conjunction with urine cytology, the test kit identified 100% of the late-stage invasive bladder cancers, whereas 45% of these conditions would have been missed using urine cytology alone
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012518

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel